The aim of the Fund is to provide a return by way of capital growth and income.
Name | % Net Assets |
---|---|
United Kingdom Gilt 4.25 07/12/2040 | 2.0% |
Bundesschatzanweisungen 0.25 13/12/2013 | 1.9% |
GlaxoSmithKline PLC | 1.7% |
Royal Dutch Shell PLC | 1.5% |
AstraZeneca PLC | 1.3% |
BT Group PLC | 1.2% |
British American Tobacco PLC | 1.1% |
United Kingdom Gilt 5.25 07/06/2012 | 1.1% |
BG Group PLC | 1.0% |
Unilever PLC | 0.9% |
Key | % Net Assets |
---|---|
United Kingdom Gilt 4.25 07/12/2040 | 2.0% |
Bundesschatzanweisungen 0.25 13/12/2013 | 1.9% |
GlaxoSmithKline PLC | 1.7% |
Royal Dutch Shell PLC | 1.5% |
Other | 92.9% |
Date | 09-Apr-2021 |
---|---|
Bid | 128.00p |
Offer | 128.00p |
Currency | GBP |
Change | 0.100p |
% | 0.08% |
YTD change | 128.00p |
YTD % | n/a |
Fund Inception | 16/10/2002 |
---|---|
Fund Manager | Quentin Fitzsimmons |
TER | 1.54 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £2000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.75% |
Annual Mang't | 0.25% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.09 |
You are here: research